Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Hims & Hers Health (HIMS)

Hims & Hers COO Nader Kabbani to step into advisory role; Mike Chi named COO

Neutral Impact 4 of 5 leadership Written later

Hims & Hers Health said COO Nader Kabbani will move into a new advisory role effective November 2, 2025, continuing to provide strategic guidance through July 2026. Chief Commercial Officer Mike Chi will become Chief Operating Officer on the same date, and the company will consolidate operations, marketing, product and commercial functions under him and will not have a separate Chief Commercial Officer.

Key points

  • Nader Kabbani determined to step into an advisory role on September 28, 2025, effective November 2, 2025, through July 2026
  • Mike Chi, 46, joined the company in April 2021 and will become Chief Operating Officer effective November 2, 2025
  • The Compensation Committee plans to review Mr. Chi's compensation in light of his expanded responsibilities; no changes have been approved
  • The company will not have a separate Chief Commercial Officer after the transition

The filing

CompanyHims & Hers Health (HIMS)
Form8-K, current report
Filed with the SECOct 2, 2025, 4:04 PM ET
Accession number0001773751-25-000331

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.